NVO logo

NVO
Novo Nordisk A/S

27,045
Mkt Cap
$169.68B
Volume
13.05M
52W High
$109.04
52W Low
$43.08
PE Ratio
14.65
NVO Fundamentals
Price
$48.96
Prev Close
$50.37
Open
$49.81
50D MA
$50.89
Beta
0.71
Avg. Volume
24.13M
EPS (Annual)
$3.29
P/B
8.37
Rev/Employee
$551,951.47
Loading...
Loading...
News
all
press releases
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S...
CNBC: Healthcare·4h ago
News Placeholder
More News
News Placeholder
Top Pharmaceutical Stocks To Consider - December 16th
Eli Lilly and Company, Pfizer, AbbVie, Bristol Myers Squibb, and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical...
MarketBeat·5h ago
News Placeholder
Eli Lilly or Merck: Where Should Investors Put Their Money?
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
Zacks·9h ago
News Placeholder
Novo Nordisk A/S $NVO Shares Purchased by Martin Capital Partners LLC
Martin Capital Partners LLC boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 53.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·11h ago
News Placeholder
87,191 Shares in Novo Nordisk A/S $NVO Bought by Shorepoint Capital Partners LLC
Shorepoint Capital Partners LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and...
MarketBeat·11h ago
News Placeholder
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Zacks·1d ago
News Placeholder
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Zacks·1d ago
News Placeholder
Reynders McVeigh Capital Management LLC Acquires New Shares in Novo Nordisk A/S $NVO
Reynders McVeigh Capital Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 2nd quarter, according to its most recent filing with the Securities...
MarketBeat·1d ago
News Placeholder
2 Predictions for Novo Nordisk in 2026
Key PointsNovo Nordisk has the potential to maintain more consistent revenue growth throughout next year...
Nasdaq News: Markets·2d ago
News Placeholder
Novo Nordisk A/S $NVO Shares Purchased by Saratoga Research & Investment Management
Saratoga Research & Investment Management boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 4.0% during the second quarter, according to the company in its most recent...
MarketBeat·2d ago
<
1
2
...
>

Latest NVO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.